Today: 9 June 2026
3M stock price tumbles on 2026 profit outlook, tariffs back in focus
20 January 2026
2 mins read

3M stock price tumbles on 2026 profit outlook, tariffs back in focus

New York, Jan 20, 2026, 13:40 EST — Regular session

  • 3M shares dropped roughly 7% following a slightly weaker-than-expected adjusted profit forecast for 2026.
  • The company warned of a possible extra impact from planned U.S. tariffs targeting European products.
  • Investors are balancing tariff concerns with indications that 3M’s margin efforts remain steady.

3M shares dropped 7.4% to $155.30 in early afternoon Tuesday, following the company’s 2026 profit forecast that fell just short of Wall Street’s estimates.

The shortfall was small, but the timing couldn’t be worse. Traders want to see clear evidence that 3M’s turnaround can push ahead despite uneven consumer demand and the return of tariff risks into earnings forecasts.

3M forecast adjusted earnings of $8.50 to $8.70 per share for 2026, with the midpoint slightly shy of the $8.61 analysts had predicted, per LSEG data. CEO Bill Brown flagged ongoing challenges in the roofing granules and automotive aftermarket segments early next year. CFO Anurag Maheshwari, meanwhile, said he anticipates “the macro in 2026 to be a little bit better.” Brown noted the forecast already factors in a 20-cent tariff impact and warned a fresh tariff threat could cost $30 million to $40 million this year. reuters.com

3M reported adjusted earnings of $1.83 per share for the fourth quarter, on adjusted sales hitting $6.0 billion. The adjusted operating margin climbed to 21.1%, up from 19.7% a year ago. Full-year adjusted EPS came in at $8.06, with sales totaling $24.3 billion. Organic growth, stripping out currency and deal impacts, stood at 2.1%. Brown highlighted that the company’s “accelerated pace of innovation and commercial execution” should help it outpace the broader economy again in 2026. 3M Company

Wall Street’s key indexes slipped in late morning trading, pressured by U.S. President Donald Trump’s latest tariff threats linked to a spat over Greenland. Tariffs are set to begin Feb. 1, Reuters reported. Jeff Buchbinder, chief equity strategist at LPL Financial, said, “We think we’ll settle down and realize this is just a negotiation tool.” reuters.com

Tariffs, essentially import taxes, can hit manufacturers like 3M quickly—whether through rising component costs or pressure on prices. Brown noted the company factored in a tariff headwind for its 2026 outlook, but the newest proposals introduce fresh uncertainty amid uneven demand.

3M’s consumer segment saw sales dip 1.2% in the October-to-December stretch. The company cited weaker retail conditions and strained discretionary spending as key factors. Softness persisted in areas linked to home improvement and high-value purchases, where volume tends to shift sharply.

There were offsets. 3M has relied on cost cutting, selective price increases, and new product launches to defend its margins. The company has also laid out longer-term goals that depend on maintaining this discipline, even if growth slows down.

Investors will keep an eye on whether this trend lasts into the first half of the year, especially if retailers and distributors start pulling back on orders. For 3M, the real question isn’t just beating one quarter’s estimates but sustaining margin growth without relying too heavily on price hikes.

Risks cut both ways. Should tariffs kick in on Feb. 1 and rise again later as warned, or if consumer demand weakens more, the earnings outlook could face pressure — particularly since litigation-related charges continue to weigh on results.

Next on the policy calendar: traders are watching to see if the tariff threat becomes actual duties on Feb. 1. They’ll also be eyeing incoming U.S. economic data for clues on demand, with 3M’s 2026 guidance now serving as the key benchmark.

Stock Market Today

  • Pro Portfolio Adds Broadcom and Netflix Shares, Upgrades Broadcom Rating
    June 9, 2026, 10:19 AM EDT. The Pro Portfolio is buying 80 shares of Broadcom (AVGO) at around $405, increasing its holdings to 512 shares (3.4% of the portfolio). It is also purchasing 372 shares of Netflix (NFLX) near $82.35, increasing its stake to 2,107 shares (2.85%). Broadcom's AI chip forecast for H2 2026 is viewed as conservative following a $35 billion private credit deal involving Apollo and Blackstone. The rating for Broadcom is upgraded to One, with a checkpoint price of $330 maintained. Netflix's shares are seen as undervalued despite recent declines, supported by a $25 billion buyback and rising U.S. viewership. Netflix's ad business shows growth potential, reaching 250 million monthly active viewers, reinforcing optimism amidst concerns over consumer spending.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Grab stock rises even as Wall Street slides after BofA upgrade — what’s next for GRAB
Previous Story

Grab stock rises even as Wall Street slides after BofA upgrade — what’s next for GRAB

Dow Jones today: Dow drops 870 points on Trump Greenland tariff threat as volatility jumps
Next Story

Dow Jones today: Dow drops 870 points on Trump Greenland tariff threat as volatility jumps

Go toTop